INTRODUCTION Cisatracurium is a potent Neuron Muscular Blocking Agent [NMBA], its ideal onset time is of 4 minutes. Cisatracurium may be used to facilitate tracheal intubation at doses equivalent to 3 to 4 times the ED95 (0.15 to 0.2 mg / kg) and when the duration of the procedure is expected to exceed 1 hour. Duration is shorter with lower doses, but onset time is prolonged and intubating conditions are less ideal.
METHODOLOGY The patients coming to Breach Candy Hospital trust during period 2018 - 2019 for surgery under general anaesthesia, who met the Inclusion Criteria.
RESULTS Distribution of subjects between groups with regards to Age, Weight, Gender, ASA grade or MPC grade was not statistically significant. In hemodynamics changes in both groups heart rate showed increasing trend. The difference was statistically significant at every time interval except at 6 min. (p value < 0.05) similarly, in systolic BP, diastolic BP and mean BP in two group difference was statistically significant above baseline.
DISCUSSION There are many neuromuscular blocking agents available to be used for general anesthesia. Cisatracurium has delayed onset of action compared to Atracurium. Better intubating conditions can be achieved early with Cisatracurium by increasing its dose, but increasing dose will increase duration of neuromuscular block. While selecting neuromuscular agent for tracheal intubation or skeletal muscle relaxation, main aim of an Anesthesiologist is to select an agent which will give better intubating conditions and does not cause much of hemodynamics response and other side effects.